Effects of rituximab in two patients with dysferlin-deficient muscular dystrophy

BACKGROUND: The administration of rituximab (RTX) in vivo results in B-cell depletion, but evidence for multiple mechanisms of action have been reported. Surprisingly, B cell depletion produced a response in patients with polymyositis, which is characterized as a T cell-mediated autoimmune disorder...

Descripción completa

Detalles Bibliográficos
Autores principales: Lerario, Alberto, Cogiamanian, Filippo, Marchesi, Chiara, Belicchi, Marzia, Bresolin, Nereo, Porretti, Laura, Torrente, Yvan
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2912795/
https://www.ncbi.nlm.nih.gov/pubmed/20618995
http://dx.doi.org/10.1186/1471-2474-11-157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2912795/
https://www.ncbi.nlm.nih.gov/pubmed/20618995
http://dx.doi.org/10.1186/1471-2474-11-157

Ejemplares similares